These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label TAP Pharmaceutical Products Inc. Prevacid Lansoprazole NCT 00175032 Ulcers, NSAID-related Phase III http://pitap.abbott.com/showpi.asp?PI=prevacid Clinical Study Summary Study LAN-0003-0041 A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID versus Celecoxib 200 mg QD in Risk Reduction of Non-Steroidal Anti-inflamatory-Associated Ulcers in Osteoarthritis Subjects taking Low Dose Aspirin. The content of this web site is supplied for informational purposes only and should not be construed as medical advice. Patients should consult their health care professional for advice on their specific situation. Nothing in TAP's posting of information is intended to be viewed as any claim for a particular marketed or unmarketed product. Some clinical studies may include information not contained in the approved package insert. Please refer to the full prescribing information for additional information. TAP Pharmaceutical Products Inc. (TAP)will use reasonable efforts to include accurate and up-to-date information consistent with TAP policies and procedures, on the ClinicalStudyResults.org web site. However because the status of studies often changes, TAP makes no warranties or representations of any kind as to the current status or completeness of the information contained therein. Persons accessing and using information posted by TAP on the ClinicalStudyResults.org web site do so at their own risk. TAP hereby disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. TAP shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use or inability to use information posted by TAP on the ClinicalStudyResults.org web site, or any errors or omission in the content thereof. To view this study on clinicaltrials.gov: http://www.clinicaltrials.gov/ct/show/NCT00175032 For FDA Safety Alerts and Recalls refer to the following link: www.fda.gov/MEDWATCH/safety.htm Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74. PubMedID: 17916545 Company Study TAP Study Synopsis LAN-0003-0041 Back to Search Results